Syn­er­gy Phar­ma preps step 2 for Tru­lance as pos­i­tive PhI­II IBS-C da­ta squares off against Iron­wood and Arde­lyx

Hot on the heels for an ap­proval of Tru­lance (ple­ca­natide) for chron­ic id­io­path­ic con­sti­pa­tion, Syn­er­gy Phar­ma $SGYP is back with pos­i­tive Phase III da­ta on ir­ri­ta­ble bow­el syn­drome, which will quick­ly trig­ger some com­par­isons with a well-es­tab­lished drug in the mar­ket as well as a late-stage drug com­ing up close be­hind.

In­ves­ti­ga­tors say that Tru­lance scored the pri­ma­ry end­point in two large stud­ies in­volv­ing 2,100 pa­tients with IBS in­volv­ing con­sti­pa­tion. Over­all re­spon­ders — those pa­tients who achieved a sig­nif­i­cant re­duc­tion in the worst ab­dom­i­nal pain along with a sig­nif­i­cant in­crease in bow­el move­ments over 6 of 12 weeks — in both dose groups out­paced the place­bo arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.